14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
LXRX vs CAPR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LXRX carries a Unified Composite Score of 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While LXRX currently prints a higher short-term Unified Composite Score (38.7/100 SELL vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -147.4% operating margin) and revenue trajectory (-7.9% vs. -20.7% YoY).
Defensive Composite Rating Caution: Although CAPR compares more favorably head-to-head, both LXRX (38.7/100 SELL) and CAPR (28.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: LXRX is currently in a Breakdown options structure phase (RSI 54.2); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LXRX vs CAPR Key Questions & Quantitative Answers
As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LXRX carries a Unified Composite Score of 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While LXRX currently prints a higher short-term Unified Composite Score (38.7/100 SELL vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -147.4% operating margin) and revenue trajectory (-7.9% vs. -20.7% YoY). Defensive Composite Rating Caution: Although CAPR compares more favorably head-to-head, both LXRX (38.7/100 SELL) and CAPR (28.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: LXRX is currently in a Breakdown options structure phase (RSI 54.2); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CAPR leads the Growth & Scale pillar: LXRX posts -20.7% YoY revenue growth and -63.4% YoY earnings growth on $39M TTM revenue (91.4% gross margin, -147.4% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LXRX cumulative revenue shifted +66.7% while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, LXRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.
CAPR screens cheaper on headline valuation multiples. LXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 21.3x EV/Revenue (unreported FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LXRX (-43.9% ROE) versus CAPR (-100.5% ROE) capital efficiency.
In options market volatility and institutional positioning, LXRX carries 78.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.62β · 60% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.